Ryo Hanajiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryo Hanajiri has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Seitaro Terakura
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
18 shared publications - Hitoshi Kiyoi
Department of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya Japan
13 shared publications - Makoto Murata
Shiga University of Medical Science, Otsu, Japan
13 shared publications - Kazuyuki Shimada
Department of Hematology and Oncology Nagoya University Graduate School of Medicine Nagoya Japan
11 shared publications - Kanae Imai
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
10 shared publications - Masahide Osaki
Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
10 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4427-4438
Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis
Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed/refractory (R/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4427-4438
Open AccessDrivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis
Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed/refractory (R/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.
- Open Access
- 11 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e012309
CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis
Background: Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has transformed the treatment of hematologic malignancies. The costimulatory domain (CSD) of CAR constructs plays a crucial role in determining T cell metabolism, persistence, and antitumor function. We previously developed a novel CSD combining CD79A and CD40, which conferred superior proliferation and antitumor efficacy compared with CD28-based or 4-1BB-based CAR-T cells. The metabolic mechanisms underlying these effects remain to be elucidated. Methods: We compared CD28, 4-1BB, and CD79A/CD40 CAR-T cells using transcriptomic analysis, metabolic flux assays, and metabolomics. Patient samples treated with 4-1BB-based or CD28-based CAR-T therapies were analyzed to assess correlations between serum lipids and CAR-T expansion. Results: Transcriptomic profiling revealed that CD79A/CD40 CAR-T cells shared gene expression patterns with 4-1BB CAR-T cells, particularly in pathways related to oxidative phosphorylation (OXPHOS) and T cell memory differentiation, but were distinct from CD28 CAR-T cells. Both 4-1BB and CD79A/CD40 CAR-T cells relied on OXPHOS and exhibited greater mitochondrial fitness, as evidenced by higher spare respiratory capacity and mitochondrial mass. Notably, CD79A/CD40 CAR-T cells displayed significantly enhanced glycolysis during the early phase following antigen stimulation, distinguishing them from 4-1BB CAR-T cells and supporting rapid initial expansion. Metabolomic profiling showed upregulation of cholesterol biosynthesis enzymes in both CD79A/CD40 and 4-1BB CAR-T cells, suggesting a shared reliance on cholesterol metabolism. Importantly, in patients treated with 4-1BB-based CAR-T therapy, higher serum low-density lipoprotein cholesterol levels positively correlated with CAR-T expansion in the late phase, particularly within CD4+T cell subsets. This relationship was not observed in patients receiving CD28-based CAR-T therapy. These findings indicate that cholesterol availability may influence CAR-T persistence in vivo, and that the metabolic phenotype of CD79A/CD40 CAR-T cells is optimized for both early proliferation and long-term survival. Conclusions: CD79A/CD40 CAR-T cells exhibit unique metabolic adaptations, including early glycolytic activation, sustained OXPHOS, and upregulated cholesterol metabolism, which together may underpin their enhanced proliferation and persistence. Targeting cholesterol metabolism may represent a novel strategy to optimize CAR-T cell function and improve therapeutic outcomes.
- 11 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e012309
Open AccessCD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis
Background: Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has transformed the treatment of hematologic malignancies. The costimulatory domain (CSD) of CAR constructs plays a crucial role in determining T cell metabolism, persistence, and antitumor function. We previously developed a novel CSD combining CD79A and CD40, which conferred superior proliferation and antitumor efficacy compared with CD28-based or 4-1BB-based CAR-T cells. The metabolic mechanisms underlying these effects remain to be elucidated. Methods: We compared CD28, 4-1BB, and CD79A/CD40 CAR-T cells using transcriptomic analysis, metabolic flux assays, and metabolomics. Patient samples treated with 4-1BB-based or CD28-based CAR-T therapies were analyzed to assess correlations between serum lipids and CAR-T expansion. Results: Transcriptomic profiling revealed that CD79A/CD40 CAR-T cells shared gene expression patterns with 4-1BB CAR-T cells, particularly in pathways related to oxidative phosphorylation (OXPHOS) and T cell memory differentiation, but were distinct from CD28 CAR-T cells. Both 4-1BB and CD79A/CD40 CAR-T cells relied on OXPHOS and exhibited greater mitochondrial fitness, as evidenced by higher spare respiratory capacity and mitochondrial mass. Notably, CD79A/CD40 CAR-T cells displayed significantly enhanced glycolysis during the early phase following antigen stimulation, distinguishing them from 4-1BB CAR-T cells and supporting rapid initial expansion. Metabolomic profiling showed upregulation of cholesterol biosynthesis enzymes in both CD79A/CD40 and 4-1BB CAR-T cells, suggesting a shared reliance on cholesterol metabolism. Importantly, in patients treated with 4-1BB-based CAR-T therapy, higher serum low-density lipoprotein cholesterol levels positively correlated with CAR-T expansion in the late phase, particularly within CD4+T cell subsets. This relationship was not observed in patients receiving CD28-based CAR-T therapy. These findings indicate that cholesterol availability may influence CAR-T persistence in vivo, and that the metabolic phenotype of CD79A/CD40 CAR-T cells is optimized for both early proliferation and long-term survival. Conclusions: CD79A/CD40 CAR-T cells exhibit unique metabolic adaptations, including early glycolytic activation, sustained OXPHOS, and upregulated cholesterol metabolism, which together may underpin their enhanced proliferation and persistence. Targeting cholesterol metabolism may represent a novel strategy to optimize CAR-T cell function and improve therapeutic outcomes.
- 14 February 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (4) , 492-495
Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy
- 14 February 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (4) , 492-495
Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy
- Open Access
- 29 November 2025
- Published by Elsevier in Cytotherapy
- Vol. 28 (3) , 102015
Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma
- 29 November 2025
- Published by Elsevier in Cytotherapy
- Vol. 28 (3) , 102015
Open AccessImpact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma
- Open Access
- 25 May 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 180-188
Robust CAR T‐cell expansion and superior outcomes in DLBCL patients in complete response at infusion
Summary: Historically, the presence of measurable disease has been considered essential to stimulate CAR T‐cell expansion and persistence. However, the kinetics of CAR T cells in patients achieving complete response (CR) before infusion remain poorly understood. This study aimed to evaluate the outcomes and CAR T‐cell kinetics in relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) patients stratified by pre‐infusion disease status. In this retrospective analysis of 87 patients treated at a single institution, 23 (26.4%) were in CR and 64 (73.6%) were in non‐CR prior to CAR T‐cell infusion. Patients in CR exhibited significantly better progression‐free survival (PFS) and overall survival compared to non‐CR patients. Peripheral blood CAR T‐cell kinetics, including the proportion and absolute counts of CAR T cells, CD4+ CAR T cells and CD8+ CART cells, showed no significant differences between CR and non‐CR groups. These findings were consistent across different CAR T‐cell products, whether 4‐1BB‐ or CD28‐based. Moreover, an analysis of patients achieving complete metabolic response (CMR) by PET‐CT confirmed comparable CAR T‐cell expansion and persistence in both CMR and non‐CMR patients. Our findings demonstrate that CAR T‐cell therapy achieves robust expansion and favourable survival outcomes in CR patients, even in the absence of measurable disease.
- 25 May 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 180-188
Open AccessRobust CAR T‐cell expansion and superior outcomes in DLBCL patients in complete response at infusion
Summary: Historically, the presence of measurable disease has been considered essential to stimulate CAR T‐cell expansion and persistence. However, the kinetics of CAR T cells in patients achieving complete response (CR) before infusion remain poorly understood. This study aimed to evaluate the outcomes and CAR T‐cell kinetics in relapsed/refractory diffuse large B‐cell lymphoma (DLBCL) patients stratified by pre‐infusion disease status. In this retrospective analysis of 87 patients treated at a single institution, 23 (26.4%) were in CR and 64 (73.6%) were in non‐CR prior to CAR T‐cell infusion. Patients in CR exhibited significantly better progression‐free survival (PFS) and overall survival compared to non‐CR patients. Peripheral blood CAR T‐cell kinetics, including the proportion and absolute counts of CAR T cells, CD4+ CAR T cells and CD8+ CART cells, showed no significant differences between CR and non‐CR groups. These findings were consistent across different CAR T‐cell products, whether 4‐1BB‐ or CD28‐based. Moreover, an analysis of patients achieving complete metabolic response (CMR) by PET‐CT confirmed comparable CAR T‐cell expansion and persistence in both CMR and non‐CMR patients. Our findings demonstrate that CAR T‐cell therapy achieves robust expansion and favourable survival outcomes in CR patients, even in the absence of measurable disease.
- Open Access
- 23 May 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (8) , 962-972
Adjustment of low-dose ATG exposure improves outcomes in allogeneic hematopoietic stem cell transplantation: a prospective multicenter study
- 23 May 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (8) , 962-972
Open AccessAdjustment of low-dose ATG exposure improves outcomes in allogeneic hematopoietic stem cell transplantation: a prospective multicenter study
- Open Access
- 7 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e009825
Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells
Background: Whereas chimeric antigen receptor gene modified T (CAR-T) cell therapy has been clinically applied to malignant lymphomas and multiple myeloma, CAR-T cell therapy for solid tumors has so far not reached clinical application. Epithelial V-like antigen 1 (Eva1), transcribed from myelin protein zero-like 2 (MPZL2), is a small surface protein highly expressed on various tumor cells. We selected Eva1 as a novel solid tumor-target antigen because of its broad expression across various tumor types. The purpose of the present study is to develop and optimize CAR-T cells targeting Eva1. Method: We prepared various humanized single chain variable fragment sequences based on a mouse anti-human Eva1 monoclonal antibody. We constructed six humanized Eva1CAR-Ts and selected one that maintained specificity and good cellular proliferation after antigen stimulation. We further optimized the length of the extracellular spacer domain and the choice of the intracellular domain in vitro and in two different xenograft mouse models. Results: We confirmed Eva1 expression on various tumor cell lines by flow cytometry and analysis of public database, but we also observed that normal monocytes weakly expressed Eva1. A combination of short spacer domain and 4-1BB or CD79A/CD40 intracellular domain provided higher treatment efficacy both in vitro and in vivo. The cytokine release on autologous monocyte stimulation to Eva1CAR-T cells was comparable to that on autologous B cell stimulation to CD19CAR-T cells. Humanized Eva1CAR-T cells demonstrated excellent therapeutic efficacy by infusing a single dose of Eva1CAR-T cells (1×106) in both NCI-H1975 lung cancer and CFPAC-1 pancreatic cancer cell line grafted model. Conclusions: In summary, these data suggest that humanized Eva1CAR-T has promising therapeutic potential for the treatment of various Eva1-positive solid tumors. Regarding on-target/off-tumor recognition, further detailed analyses of the Eva1CAR-T cell responses to normal tissues are needed.
- 7 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e009825
Open AccessDevelopment and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells
Background: Whereas chimeric antigen receptor gene modified T (CAR-T) cell therapy has been clinically applied to malignant lymphomas and multiple myeloma, CAR-T cell therapy for solid tumors has so far not reached clinical application. Epithelial V-like antigen 1 (Eva1), transcribed from myelin protein zero-like 2 (MPZL2), is a small surface protein highly expressed on various tumor cells. We selected Eva1 as a novel solid tumor-target antigen because of its broad expression across various tumor types. The purpose of the present study is to develop and optimize CAR-T cells targeting Eva1. Method: We prepared various humanized single chain variable fragment sequences based on a mouse anti-human Eva1 monoclonal antibody. We constructed six humanized Eva1CAR-Ts and selected one that maintained specificity and good cellular proliferation after antigen stimulation. We further optimized the length of the extracellular spacer domain and the choice of the intracellular domain in vitro and in two different xenograft mouse models. Results: We confirmed Eva1 expression on various tumor cell lines by flow cytometry and analysis of public database, but we also observed that normal monocytes weakly expressed Eva1. A combination of short spacer domain and 4-1BB or CD79A/CD40 intracellular domain provided higher treatment efficacy both in vitro and in vivo. The cytokine release on autologous monocyte stimulation to Eva1CAR-T cells was comparable to that on autologous B cell stimulation to CD19CAR-T cells. Humanized Eva1CAR-T cells demonstrated excellent therapeutic efficacy by infusing a single dose of Eva1CAR-T cells (1×106) in both NCI-H1975 lung cancer and CFPAC-1 pancreatic cancer cell line grafted model. Conclusions: In summary, these data suggest that humanized Eva1CAR-T has promising therapeutic potential for the treatment of various Eva1-positive solid tumors. Regarding on-target/off-tumor recognition, further detailed analyses of the Eva1CAR-T cell responses to normal tissues are needed.
- 27 February 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 122 (1) , 106-116
Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever
Chimeric antigen receptor T-cell (CAR-T)-related adverse events (CAR-AEs), such as immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS), can be life-threatening and may require high-dose steroids. Identifying patients at high risk for severe CAR-AEs in a simplified way is crucial for early therapeutic intervention. This retrospective study analyzed 44 patients treated with axicabtagene ciloleucel (Axi-cel) to identify predictive factors for severe CAR-AEs. We found that grade ≥ 3 ICANS, hemophagocytic syndrome, and ICU admission were associated with a greater need for high-dose steroids, which we defined as events associated with high-dose steroids (EHS). The incidence of EHS was significantly higher in patients who developed an initial fever (≥ 38.6 °C) within 24 h of CAR-T infusion (p < 0.001). Progression-free survival (PFS) was significantly shorter in patients with EHS compared to those without EHS (p < 0.001). Additionally, patients who developed a fever within 24 h and those with a peak fever of ≥ 38.6 °C both tended to have higher peak CAR-T counts compared to other patients. Our findings suggest that an initial fever (≥ 38.6 °C) within 24 h of Axi-cel infusion may predict severe CAR-AEs requiring high-dose steroids, and that EHS is associated with worse PFS.
- 27 February 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 122 (1) , 106-116
Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever
Chimeric antigen receptor T-cell (CAR-T)-related adverse events (CAR-AEs), such as immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS), can be life-threatening and may require high-dose steroids. Identifying patients at high risk for severe CAR-AEs in a simplified way is crucial for early therapeutic intervention. This retrospective study analyzed 44 patients treated with axicabtagene ciloleucel (Axi-cel) to identify predictive factors for severe CAR-AEs. We found that grade ≥ 3 ICANS, hemophagocytic syndrome, and ICU admission were associated with a greater need for high-dose steroids, which we defined as events associated with high-dose steroids (EHS). The incidence of EHS was significantly higher in patients who developed an initial fever (≥ 38.6 °C) within 24 h of CAR-T infusion (p < 0.001). Progression-free survival (PFS) was significantly shorter in patients with EHS compared to those without EHS (p < 0.001). Additionally, patients who developed a fever within 24 h and those with a peak fever of ≥ 38.6 °C both tended to have higher peak CAR-T counts compared to other patients. Our findings suggest that an initial fever (≥ 38.6 °C) within 24 h of Axi-cel infusion may predict severe CAR-AEs requiring high-dose steroids, and that EHS is associated with worse PFS.
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).
- Open Access
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).
- 4 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Supplemental Figure S3. Analysis of differentiation markers of CAR-T cells. Each CAR-T cells and tEGFR-T cells were stimulated with CD19/CD37 positive Raji cells at a 1:5 ratio every 7 days and stained for CD62L, CD45RA, CCR7, CD27 and CD28. A, B, Summary data of the percentage of CD45RA-/CD62L+ central memory T (TCM) cell fraction (A) and CD45RA-/CD62L- effecter memory T (TEM) cell fraction (B). C–E, Summary data of the percentage of CCR7-/CD27+/CD28+ early TEM cell fraction (C), CCR7-/CD27+/CD28- late TEM cell fraction (D) and CCR7-/CD27-/CD28- effecter T cell fraction (E). Data represent mean ± SEM from five different donors (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001).